The DOI matches its Crossref record.
Gadolinium-Contrast Toxicity in Patients with Kidney Disease: Nephrotoxicity and Nephrogenic Systemic Fibrosis
Abstract
Gadolinium is widely employed as a contrast agent for magnetic resonance imaging (MRI) and has generally been considered to be safe. As with iodinated radiocontrast, concern for contrast-induced nephropathy existed with gadolinium-contrast as it possessed many similar qualities (hyperosmolar, renal excretion via glomerular filtration). Early studies in low risk patients suggested a benign renal profile, however, recent studies raise the possibility of nephrotoxicity. In addition, reports of a previously rare condition entitled nephrogenic systemic fibrosis (NSF) have recently emerged in patients with advanced kidney disease and have been linked to exposure to gadolinium-contrast. Nephrogenic systemic fibrosis is a debilitating disorder in which progressive and severe fibrosis of the skin and other systemic organs that leads to significant disability and is associated with increased mortality. Initially reported most commonly in end stage renal disease (ESRD) patients receiving dialysis, it is also described in patients with severe acute kidney injury (AKI) and advanced chronic kidney disease (stages 4 and 5) not requiring dialysis. In addition to underlying kidney disease, the risk of developing NSF is increased with larger doses of gadolinium (or multiple exposures), exposure to specific gadolinium chelates (non-ionic, linear), underlying pro-inflammatory states (in particular vascular endothelial dysfunction), and perhaps some currently unrecognized cofactors. No clearly effective therapies exist for NSF, although recovery from AKI and establishment of normal kidney function with renal transplantation appear to reverse or stabilize the disease in some cases. Avoidance of gadolinium exposure appears to be the best approach for patients who maintain risk factors. When gadolinium exposure occurs, aggressive hemodialysis following exposure may be useful as gadolinium is efficiently removed by this extracorporeal technique. Peritoneal dialysis clearance of gadolinium is poor, but aggressive peritoneal dialysis prescriptions have not been studied for gadolinium removal.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cited by
X-ray-Computed Tomography Contrast Agents
Lusic, H., & Grinstaff, M. W. (2013) · Chemical Reviews · doi:10.1021/cr200358s · Cited by 1,108
Upconverting nanoparticles: assessing the toxicity
Gnach, A., Lipinski, T., Bednarkiewicz, A., Rybka, J., & Capobianco, J. A. (2015) · Chemical Society Reviews · doi:10.1039/c4cs00177j · Cited by 652
Single-breath-hold photoacoustic computed tomography of the breast
Lin, L., Hu, P., Shi, J., Appleton, C. M., Maslov, K., Li, L., Zhang, R., & Wang, L. V. (2018) · Nature Communications · doi:10.1038/s41467-018-04576-z · Cited by 454
Clinical Practice Guideline: Hoarseness (Dysphonia)
Schwartz, S. R., Cohen, S. M., Dailey, S. H., Rosenfeld, R. M., Deutsch, E. S., Gillespie, M. B., Granieri, E., Hapner, E. R., Kimball, C. E., Krouse, H. J., et al. (2009) · Otolaryngology–Head and Neck Surgery · doi:10.1016/j.otohns.2009.06.744 · Cited by 453
Clinical Practice Guideline: Hoarseness (Dysphonia) (Update)
Stachler, R. J., Francis, D. O., Schwartz, S. R., Damask, C. C., Digoy, G. P., Krouse, H. J., McCoy, S. J., Ouellette, D. R., Patel, R. R., Reavis, C. (. W., et al. (2018) · Otolaryngology–Head and Neck Surgery · doi:10.1177/0194599817751030 · Cited by 368
Metadata
- Authors
- Perazella, M.
- Venue
- Current Drug Safety
- Publisher
- Bentham Science Publishers Ltd.
- Published
- 2008-01-01
- Volume
- 3
- Issue
- 1
- Pages
- 67-75
- ISSN
- 1574-8863 (ISSN-L)
- OpenAlex
- W1984357202
- Cited by
- 164
- References
- 0
- FWCI
- 6.06
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Gadolinium-Contrast Toxicity in Patients with Kidney Disease: Nephrotoxicity and Nephrogenic Systemic Fibrosis. https://app.cochat.ai/papers/10.2174/157488608783333989
- The paper
- Perazella, M. (2008). Gadolinium-Contrast Toxicity in Patients with Kidney Disease: Nephrotoxicity and Nephrogenic Systemic Fibrosis. Current Drug Safety. https://doi.org/10.2174/157488608783333989
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.